Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
- PMID: 36698726
- PMCID: PMC9869782
- DOI: 10.2147/IDR.S396428
Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
Abstract
Purpose: The rising incidence of carbapenem-resistant Pseudomonas aeruginosa (PA) bloodstream infection (BSI) has made the selection of antibiotic therapy more difficult and caused high mortality. This study was aimed at exploring the risk factors for carbapenem-resistant Pseudomonas aeruginosa (CRPA) bloodstream infection and identifying the risk factors for the outcomes of patients with PA-BSI.
Methods: We performed a retrospective cohort study of patients with PA-BSI in a tertiary hospital from January 2017 to December 2021 in China. Epidemiological, clinical, and microbiological characteristics were described. Risk factors for CRPA-BSI and the outcomes of PA-BSI inpatients were identified, using multivariate logistic regression analysis.
Results: A total of 198 PA-BSI inpatients were included. The negative outcome rate was significantly higher in patients infected with CRPA (15/34, 44.12%) than with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) (35/164, 21.34%), and the difference was statistically significant (P=0.005). Multivariate logistic regression analysis showed that previous exposure to carbapenem (OR 3.519, 95% CI 1.359-9.110, P=0.010) was an independent risk factor for CRPA-BSI. In addition, CRPA (OR 1.615, 95% CI 0.626-4.171, P=0.32) was not an independent risk factor for negative outcome among PA-BSI inpatients.
Conclusion: Our study showed that previous exposure to carbapenem was an independent risk factor for CRPA-BSI. CRPA was not an independent risk factor for a negative outcome in PA-BSI inpatients.
Keywords: Pseudomonas aeruginosa bloodstream infection; carbapenem-resistant; outcomes; risk factors.
© 2023 Wei et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest in this work.
Similar articles
-
Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infections in Cancer Patients: An 8-year Retrospective Study in a Tertiary Cancer Hospital.Infect Drug Resist. 2025 May 15;18:2511-2524. doi: 10.2147/IDR.S515530. eCollection 2025. Infect Drug Resist. 2025. PMID: 40390797 Free PMC article.
-
Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study.Front Microbiol. 2023 May 18;14:1137811. doi: 10.3389/fmicb.2023.1137811. eCollection 2023. Front Microbiol. 2023. PMID: 37260693 Free PMC article.
-
Risk Factors for Development and Mortality of Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection in a Chinese Teaching Hospital: A Seven-Year Retrospective Study.Infect Drug Resist. 2025 Feb 18;18:979-991. doi: 10.2147/IDR.S495240. eCollection 2025. Infect Drug Resist. 2025. PMID: 39990780 Free PMC article.
-
Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.Clin Microbiol Infect. 2019 Aug;25(8):964-970. doi: 10.1016/j.cmi.2019.04.005. Epub 2019 Apr 14. Clin Microbiol Infect. 2019. PMID: 30995530
-
[A systematic review and expert's analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain].Rev Esp Quimioter. 2021 Aug;34(4):298-307. doi: 10.37201/req/034.2021. Epub 2021 Apr 29. Rev Esp Quimioter. 2021. PMID: 33913312 Free PMC article. Spanish.
Cited by
-
Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China.Sci Rep. 2025 Jul 1;15(1):20719. doi: 10.1038/s41598-025-07820-x. Sci Rep. 2025. PMID: 40596677 Free PMC article.
-
Prevalence of multidrug resistant gram-negative bacteria and associated factors among gram-negative blood culture isolates at Tikur Anbessa Specialized Hospital: a retrospective study.BMC Infect Dis. 2025 Aug 8;25(1):1006. doi: 10.1186/s12879-025-11328-0. BMC Infect Dis. 2025. PMID: 40781593 Free PMC article.
-
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.Infection. 2024 Aug;52(4):1235-1268. doi: 10.1007/s15010-024-02313-x. Epub 2024 Jul 2. Infection. 2024. PMID: 38954392 Free PMC article. Review.
-
Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infections in Cancer Patients: An 8-year Retrospective Study in a Tertiary Cancer Hospital.Infect Drug Resist. 2025 May 15;18:2511-2524. doi: 10.2147/IDR.S515530. eCollection 2025. Infect Drug Resist. 2025. PMID: 40390797 Free PMC article.
-
Pseudomonas Phage Lydia and the Evolution of the Mesyanzhinovviridae Family.Viruses. 2025 Mar 4;17(3):369. doi: 10.3390/v17030369. Viruses. 2025. PMID: 40143297 Free PMC article.
References
-
- Raúl Recio MM, Esther V, Jennifer V, María Ángeles O, Jaime L-T, Fernando C. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence. Antimicrob Agents Chemother. 2020;64(2):e01759–01719. doi:10.1128/AAC.01759-19 - DOI - PMC - PubMed
-
- Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707–719. doi:10.1080/14787210.2022.2020099 - DOI - PubMed
LinkOut - more resources
Full Text Sources